-
Anavex Life Sciences Corp. NASDAQ:AVXL Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer's disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson's disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising preclinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation.
Location: 51 W 52nd St Fl 7th, New York, 10019-6163, US | Website: anavex.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
345.9M
Cash
138.8M
Avg Qtr Burn
-7.501M
Short % of Float
21.78%
Insider Ownership
3.05%
Institutional Own.
31.94%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ANAVEX 2-73 (blarcamesine) (RS-002) Details Rett syndrome | Phase 3 Update | |
ANAVEX 2-73 (Blarcamesine) Details Parkinson's disease | Phase 3 Initiation | |
ANAVEX 2-73 (Blarcamesine) Details Alzheimer's disease | Phase 2/3 Data readout | |
ANAVEX 2-73 (blarcamesine) (2-73-RS-003) Details Rett syndrome | Phase 2/3 Update | |
ANAVEX 2-73 (blarcamesine) Details Fragile X syndrome | Phase 2/3 Initiation | |
ANAVEX 3-71 (AF710B) Details Schizophrenia | Phase 2 Data readout |